Aktis Oncology, Inc. (AKTS)
D
Pipeline Grade
Financial Position (from SEC Filings)
$372.8M
Cash & Equivalents
$24.2M
Quarterly Burn Rate
46 mo
Est. Cash Runway
$1,541M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07581184 | A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer | PHASE1 | Recruiting | 138 |
| NCT07020117 | A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors | PHASE1 | Recruiting | 150 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.